Beyond Labels: Can Biomarkers and Treatable Traits Revolutionize Interstitial Lung Disease Care?

The classification of interstitial lung disease (ILD)s has traditionally relied on well-defined diagnostic labels, such as idiopathic pulmonary fibrosis (IPF), nonspecific interstitial pneumonia (NSIP), and hypersensitivity pneumonitis (HP) [...]

Uloženo v:
Podrobná bibliografie
Vydáno v:Biomedicines Ročník 13; číslo 10; s. 2467
Hlavní autoři: Amati, Francesco, Stainer, Anna, Aliberti, Stefano
Médium: Journal Article
Jazyk:angličtina
Vydáno: Switzerland MDPI AG 10.10.2025
Témata:
Biological markers
Biomarkers
Clinical trials
Diagnosis
Drug therapy
Health aspects
Lung diseases
Lung diseases, Interstitial
n/a
Patients
Physiological aspects
Precision medicine
Pulmonary fibrosis
Sarcoidosis
Italy
ISSN:2227-9059, 2227-9059
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:The classification of interstitial lung disease (ILD)s has traditionally relied on well-defined diagnostic labels, such as idiopathic pulmonary fibrosis (IPF), nonspecific interstitial pneumonia (NSIP), and hypersensitivity pneumonitis (HP) [...]
Bibliografie:SourceType-Scholarly Journals-1
content type line 14
ObjectType-Editorial-2
ObjectType-Commentary-1
content type line 23
ISSN:2227-9059
2227-9059
DOI:10.3390/biomedicines13102467